DefiniGEN’s iPS Differentiation service utilizes our proprietary OptiDIFF platform to generate high functionality terminally differentiated custom cell products to fit client specifications. The OptiDIFF platform was developed from world-leading research undertaken at the University of Cambridge and has been demonstrated on a range of cell types. The client receives fully differentiated rigorously QCed cell products which are genotype and phenotype verified in a highly relevant physiological background.
OptiDIFF platform overviewing the production of human hepatocytes, pancreatic, lung and additional cell types from human iPSC via the replication of key stages in vivo development using defined conditions.
5 step process for iPS line using best-in-class OptiDIFF for the differentiation of choice
iPS Differentiation projects are typically completed within 2-3 months. Actual timelines will vary depending on the unique aspects of each bespoke project.
Selected platform publications
Generation of Hepatocytes from Pluripotent Stem Cells for Drug Screening and Developmental Modeling. Gieseck RL 3rd, Vallier L, Hannan NR. Methods Mol Biol. 2015;1250:123-42.
Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Sampaziotis F, Vallier L et al Nature Biotechnol. 2015 Aug; 33(8): 845–852.
Generation of Distal Airway Epithelium from Multipotent Human Foregut Stem Cells. Hannan NR, Sampaziotis F, Segeritz CP, Hanley NA, Vallier L. Stem Cells Dev. 2015 Jul 15;24(14):1680-90.
Production of hepatocyte-like cells from human pluripotent stem cells. Hannan NR, Vallier L et al. Nature Protocols. 2013 Feb;8(2):430-7.
Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells. Cho C , Hannan NR, Vallier L et al. Diabetologia. 2012 Dec 55(12):3284-95.
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Yusa K, Rashid ST, Vallier L et al. Nature. 2011 Oct 12;478(7369):391-4.
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. Rashid ST, Lomas DA, Vallier L et al. J Clin Invest. 2010 Sep;120(9):3127-36.